West Lafayette-Based Endocyte Aquired For $2.1 Billion By Pharma Giant Novartis

Samantha Horton

Article origination IPBS-RJC

West Lafayette-Based Endocyte Aquired For $2.1 Billion By Pharma Giant Novartis

Swiss pharmaceutical giant Novartis says it will acquire West Lafayette-based Endocyte for $2.1 billion.

Endocyte was founded in Purdue Research Park and has been working for more than two decades to develop personalized cancer treatments that are more targeted to a specific patient’s cancer than traditional, broad-spectrum radiation therapy.

In the company’s press release, Endocyte president and CEO Mike Sherman says the acquisition will allow for a prostate cancer drug that’s now in late-stage clinical trials to have what he calls better "global reach" with Novartis’s expertise.

Earlier this month, Endocyte was the first Purdue startup to reach $1.5 billion in valuation.

Company executives did not respond to a request for comment.

Tags:Purdue University pharmaceuticals

Support independent journalism today. You rely on WFYI to stay informed, and we depend on you to make our work possible. Donate to power our nonprofit reporting today. Give now.

Indiana FSSA asks court to suspend ruling, says state medicaid expansion at risk

The Indiana Family and Social Services Administration filed a motion to prevent a federal ruling from vacating the 2020 approval of the Healthy Indiana Plan or HIP.

Health / July 11, 2024

Healthy Indiana Plan lawsuit ruling just in time to prevent Medicaid loss, advocates say

A recent federal ruling stopped Indiana's plan to bring back monthly payments for Medicaid members on the Healthy Indiana Plan, or HIP. Advocates say people will be less likely to lose Medicaid coverage as a result.

Health / July 1, 2024

FSSA: HIP cost-sharing will remain paused after federal ruling vacated program approval

Medicaid members on the Healthy Indiana Plan will not have monthly payments for the foreseeable future. The Family and Social Services Administration made the announcement after a federal judge vacated the 2020 approval of an Indiana Medicaid program over a number of policies that act as barriers to coverage.